Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meds Apotek AB (publ)FRA:24R +0.46%9 EV-to-EBITDA is 16.95 as of Sep. 08, 2026, which is 52% below its 10-year median of 35.29. GuruFocus rates FRA:24R with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 958 Retail - Cyclical companies, Meds Apotek AB (publ) ranks worse than 79.02% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Meds Apotek AB (publ)'s enterprise value is €37.13 Mil.
Meds Apotek AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €2.19 Mil. Therefore, Meds Apotek AB (publ)'s EV-to-EBITDA for today is 16.95.
The historical rank and industry rank for Meds Apotek AB (publ)'s EV-to-EBITDA or its related term are showing as below:
FRA:24R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.3 Med: 35.29 Max: 51.85
Current: 17.3
During the past 4 years, the highest EV-to-EBITDA of Meds Apotek AB (publ) was 51.85. The lowest was 13.30. And the median was 35.29.
FRA:24R's EV-to-EBITDA is ranked worse than 79.02% of 958
companies
in the Retail - Cyclical industry
Industry Median: 8.68
vs FRA:24R: 17.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Meds Apotek AB (publ) (FRA:24R) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Meds Apotek AB (publ)'s PE Ratio (TTM) for today is calculated as:
Meds Apotek AB (publ)'s share price for today is €2.19.
Meds Apotek AB (publ)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.069.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Meds Apotek AB (publ) EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Meds Apotek AB (publ)'s EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:24R vs AMZN, BABA, PDD: EV-to-EBITDA Comparison
For the Internet Retail subindustry, Meds Apotek AB (publ)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meds Apotek AB (publ) EV-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Meds Apotek AB (publ)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Meds Apotek AB (publ)'s EV-to-EBITDA falls into.
Meds Apotek AB (publ)'s current Enterprise Value is €37.13 Mil.
Meds Apotek AB (publ)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meds Apotek AB (publ) (FRA:24R) has a EV-to-EBITDA of 16.95 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Meds Apotek AB (publ). This is 52% below median its historical median of 35.29. Over the past decade, Meds Apotek AB (publ)'s EV-to-EBITDA has ranged from 13.30 to 51.85. According to the industry distribution chart, Meds Apotek AB (publ) ranks #757 out of 958 companies in the Retail - Cyclical industry, placing it in the top 79%.
Is Meds Apotek AB (publ)'s EV-to-EBITDA too high?
Meds Apotek AB (publ)'s current EV-to-EBITDA of 16.95 is 52% below median its 10-year median of 35.29. Over the past 10 years, this metric has ranged from a low of 13.30 to a high of 51.85. The Retail - Cyclical industry median EV-to-EBITDA is 8.68. Meds Apotek AB (publ)'s value of 16.95 is 95.3% above this industry median. Based on the distribution chart, Meds Apotek AB (publ) ranks #757 out of 958 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Meds Apotek AB (publ) has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Meds Apotek AB (publ)'s EV-to-EBITDA compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Meds Apotek AB (publ) ranks #757 out of 958 companies for EV-to-EBITDA. This places Meds Apotek AB (publ) in the lower half of its industry. The industry median EV-to-EBITDA is 8.68. Meds Apotek AB (publ)'s value of 16.95 is 95.3% above this benchmark. Historically, Meds Apotek AB (publ)'s own EV-to-EBITDA has ranged from 13.30 to 51.85 over the past decade. While the company's 10-year median is 35.29 vs. the industry median of 8.68, Meds Apotek AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Retail - Cyclical company?
The median EV-to-EBITDA among Retail - Cyclical companies is 8.68, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meds Apotek AB (publ)'s current EV-to-EBITDA of 16.95 is 95.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Meds Apotek AB (publ). For the Retail - Cyclical industry, the median EV-to-EBITDA is 8.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meds Apotek AB (publ)'s current EV-to-EBITDA is 16.95, which is 52% below median its own 10-year median of 35.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meds Apotek AB (publ) stock overvalued right now?
Meds Apotek AB (publ) (FRA:24R) has a current EV-to-EBITDA of 16.95. The current EV-to-EBITDA is 16.95, which is 52% below median its 10-year median of 35.29 and 95.3% above the Retail - Cyclical industry median of 8.68. Meds Apotek AB (publ)'s overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Meds Apotek AB (publ) (FRA:24R), the current EV-to-EBITDA is 16.95 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Meds Apotek AB (publ) is a full-scale online pharmacy that sells prescription and over-the-counter medicines with permission from the Medical Products Agency, the Swedish Food Agency and the E-Health Agency. The company's pharmacy products include everything in health, well-being, dietary supplements, beauty products, children's products, fitness products, food and drink and home & household products.
9GF Score
Get the complete analysis for FRA:24R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:24R has been successfully added to your 
